Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 4/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20702650 | 0.81 | — | — | |
| SCHEMBL12029861 | 0.81 | PIK3CD (0.44) | CYP1A2TDP1CYP2C9CYP3A4ALDH1A1 | |
| SCHEMBL19341299 | 0.80 | CHRNB2 (0.36) | CYP1A2CYP2C9ALDH1A1EPHX2MEN1 | |
| SCHEMBL24713771 | 0.79 | — | — | |
| SCHEMBL8380431 | 0.79 | CYP1A2 (0.41) | CYP1A2TDP1CYP2C9CYP3A4ALDH1A1 | |
| SCHEMBL21655189 | 0.79 | OPRM1 (0.41) | TDP1CYP3A4ALDH1A1KDM4EUSP2 | |
| SCHEMBL12029867 | 0.76 | PIK3CD (0.40) | CYP1A2TDP1CYP2C9CYP3A4ALDH1A1 | |
| SCHEMBL10093511 | 0.75 | CYP1A2 (0.50) | CYP1A2TDP1CYP2C9CYP3A4ALDH1A1 | |
| SCHEMBL22681510 | 0.75 | ALDH1A1 (0.33) | TDP1CYP3A4ALDH1A1KDM4EUSP2 | |
| SCHEMBL29341868 | 0.74 | ALDH1A1 (0.52) | CYP1A2CYP2C9CYP3A4ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426640-B1 | PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2020-11-18 | — | — | EP | disclosed |
| EP-3426647-B1 | TETRAHYDROISOQUINOLINES AS PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2020-11-18 | — | — | EP | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-19 | — | — | US | disclosed |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-10-05 | — | — | US | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153518-A1 | PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153515-A1 | TETRAHYDROISOQUINOLINES AS PRMT5-INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| WO-2016034671-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016034673-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | CYP1A2 820/4885TDP1 1710/4885CYP2C9 1866/4885 |
| US-20170298075-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | CYP1A2 1959/4885TDP1 2047/4885CYP2C9 2587/4885 |
| US-20170283407-A1 | TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS | PRMT5, PRMT3, PRMT1 | CYP1A2 1990/4885TDP1 2159/4885CYP2C9 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.